Advertisement
Screener

COMPASS PATHWAYS PLC (CMPS) Interest Expense on Debt

2.8 / 5 stars · 68/120 Roast Me

COMPASS PATHWAYS PLC Interest Expense on Debt

COMPASS PATHWAYS PLC (CMPS) reported Interest Expense on Debt of $2.90 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.

Financial Statements › Expense Statement › Interest Expense

us-gaap:InterestExpenseDebt · last filed 2026-08-05

  • COMPASS PATHWAYS PLC interest expense, debt for the quarter ending 2026-06-30 was $1.40M, a 0.00% change year-over-year.
  • COMPASS PATHWAYS PLC interest expense, debt for the quarter ending 2026-03-31 was $1.50M, a 66.67% increase year-over-year.
  • COMPASS PATHWAYS PLC interest expense, debt for the quarter ending 2025-12-31 was $1.10M, a 8.33% decline year-over-year.
  • COMPASS PATHWAYS PLC interest expense, debt for the quarter ending 2025-09-30 was $1.10M, a 0.00% change year-over-year.
  • COMPASS PATHWAYS PLC interest expense, debt for fiscal 2025 was $4.50M, a 0.00% change from fiscal 2024.
  • COMPASS PATHWAYS PLC interest expense, debt for fiscal 2024 was $4.50M, a 104.55% increase from fiscal 2023.
  • COMPASS PATHWAYS PLC interest expense, debt for fiscal 2023 was $2.20M.
Period endInterest Expense, Debt 3 monthInterest Expense, Debt 6 monthInterest Expense, Debt 6 month as first filedInterest Expense, Debt 9 monthInterest Expense, Debt 12 month
2026-06-30$1.40M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05
$2.90M
10-Q · filed 2026-08-05
$4.00M
derived: sum of 3 quarters · filed 2026-08-05
$5.10M
derived: sum of 4 quarters · filed 2026-08-05
2026-03-31$1.50M
10-Q · filed 2026-05-13
$2.60M
derived: sum of 2 quarters · filed 2026-05-13
$3.70M
derived: sum of 3 quarters · filed 2026-05-13
$5.10M
derived: sum of 4 quarters · filed 2026-08-05
2025-12-31$1.10M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24
$2.20M
derived: sum of 2 quarters · filed 2026-03-24
$3.60M
derived: sum of 3 quarters · filed 2026-08-05
$4.50M
10-K · filed 2026-03-24
2025-09-30$1.10M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04
$2.50M
derived: sum of 2 quarters · filed 2026-08-05
$3.40M
10-Q · filed 2025-11-04
$4.60M
derived: sum of 4 quarters · filed 2026-08-05
2025-06-30$1.40M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05
$2.30M
10-Q · filed 2026-08-05
$3.50M
derived: sum of 3 quarters · filed 2026-08-05
$4.60M
derived: sum of 4 quarters · filed 2026-08-05
2025-03-31$900.00K
10-Q · filed 2026-05-13
$2.10M
derived: sum of 2 quarters · filed 2026-05-13
$3.20M
derived: sum of 3 quarters · filed 2026-05-13
$4.30M
derived: sum of 4 quarters · filed 2026-05-13
2024-12-31$1.20M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24
$2.30M
derived: sum of 2 quarters · filed 2026-03-24
$3.40M
derived: sum of 3 quarters · filed 2026-03-24
$4.50M
10-K · filed 2026-03-24
2024-09-30$1.10M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04
$2.20M
derived: sum of 2 quarters · filed 2025-11-04
$3.30M
10-Q · filed 2025-11-04
$4.40M
derived: sum of 4 quarters · filed 2025-11-04
2024-06-30$1.10M
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-31
$2.20M
10-Q · filed 2025-07-31
$3.30M
derived: sum of 3 quarters · filed 2025-07-31
$4.40M
derived: sum of 4 quarters · filed 2025-07-31
2024-03-31$1.10M
10-Q · filed 2025-05-08
$2.20M
derived: sum of 2 quarters · filed 2025-05-08
$3.30M
derived: sum of 3 quarters · filed 2025-05-08
$3.30M
derived: sum of 4 quarters · filed 2025-05-08
2023-12-31$1.10M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27
$2.20M
derived: sum of 2 quarters · filed 2025-02-27
$2.20M
derived: sum of 3 quarters · filed 2025-02-27
$2.20M
10-K · filed 2025-02-27
2023-09-30$1.10M
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31
$1.10M
derived: sum of 2 quarters · filed 2024-10-31
$1.10M
10-Q · filed 2024-10-31
2023-06-30$0.00
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01
$0.00
10-Q · filed 2024-08-01
$100.00K
10-Q · filed 2023-08-03
2023-03-31$0.00
10-Q · filed 2024-05-08

Similar stocks

Stock NameCountryMarket CapPE Ratio
ANI PHARMACEUTICALS INC (ANIP)United States$1.810B18.77
Septerna, Inc. (SEPN)United States$1.783B-63.01
Xencor Inc (XNCR)United States$1.776B-7.33
Zymeworks Inc. (ZYME)United States$1.902B-12.44
Eton Pharmaceuticals, Inc. (ETON)United States$1.701B80.74
Sarepta Therapeutics, Inc. (SRPT)United States$1.941B-13.89
AGIOS PHARMACEUTICALS, INC. (AGIO)United States$1.962B-5.38
Biohaven Ltd. (BHVN)United States$1.990B-3.83
Xeris Biopharma Holdings, Inc. (XERS)United States$1.632B-80.10
Stoke Therapeutics, Inc. (STOK)United States$1.630B-9.82